TY - JOUR
T1 - Reproductive Outcomes of Women with Turner Syndrome Undergoing Oocyte Vitrification
T2 - A Retrospective Multicenter Cohort Study
AU - Nadesapillai, Sapthami
AU - Mol, Femke
AU - Broer, Simone L.
AU - Stevens Brentjens, Linda B. P. M.
AU - Verhoeven, Marieke O.
AU - Heida, Karst Y.
AU - Goddijn, Mariëtte
AU - van Golde, Ron J. T.
AU - Bos, Annelies M. E.
AU - van der Coelen, Sanne
AU - Peek, Ronald
AU - Braat, Didi D. M.
AU - van der Velden, Janielle A. E. M.
AU - Fleischer, Kathrin
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Background: Turner syndrome (TS) is accompanied with premature ovarian insufficiency. Oocyte vitrification is an established method to preserve fertility. However, data on the oocyte yield in women with TS who vitrify their oocytes and the return rate to utilize the oocytes are scarce. Methods: Retrospective multicenter cohort study. Data was collected from medical records of women with TS who started oocyte vitrification between 2010 and 2021. Results: Thirty-three women were included. The median cumulative number of vitrified oocytes was 20 per woman. Complications occurred in 4% of the cycles. Significant correlations were found between the cumulative number of vitrified oocytes and AMH (r = 0.54 and p < 0.01), AFC (r = 0.49 and p < 0.01), percentage of 46,XX cells (r = 0.49 and p < 0.01), and FSH (r = −0.65 and p < 0.01). Spontaneous (n = 8) and IVF (n = 2) pregnancies occurred in 10 women ± three years after vitrification. So far, none of the women have returned to utilize their vitrified oocytes. Conclusions: Oocyte vitrification is a feasible fertility preservation option for women with TS, particularly in those with 46,XX cell lines or sufficient ovarian reserve. Multiple stimulation cycles are recommended to reach an adequate number of vitrified oocytes for pregnancy. It is too early to draw conclusions about the utilization of vitrified oocytes in women with TS.
AB - Background: Turner syndrome (TS) is accompanied with premature ovarian insufficiency. Oocyte vitrification is an established method to preserve fertility. However, data on the oocyte yield in women with TS who vitrify their oocytes and the return rate to utilize the oocytes are scarce. Methods: Retrospective multicenter cohort study. Data was collected from medical records of women with TS who started oocyte vitrification between 2010 and 2021. Results: Thirty-three women were included. The median cumulative number of vitrified oocytes was 20 per woman. Complications occurred in 4% of the cycles. Significant correlations were found between the cumulative number of vitrified oocytes and AMH (r = 0.54 and p < 0.01), AFC (r = 0.49 and p < 0.01), percentage of 46,XX cells (r = 0.49 and p < 0.01), and FSH (r = −0.65 and p < 0.01). Spontaneous (n = 8) and IVF (n = 2) pregnancies occurred in 10 women ± three years after vitrification. So far, none of the women have returned to utilize their vitrified oocytes. Conclusions: Oocyte vitrification is a feasible fertility preservation option for women with TS, particularly in those with 46,XX cell lines or sufficient ovarian reserve. Multiple stimulation cycles are recommended to reach an adequate number of vitrified oocytes for pregnancy. It is too early to draw conclusions about the utilization of vitrified oocytes in women with TS.
KW - Turner syndrome
KW - fertility preservation
KW - oocyte vitrification
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85175200399&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/jcm12206502
DO - https://doi.org/10.3390/jcm12206502
M3 - Article
C2 - 37892640
SN - 0009-9147
VL - 12
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 20
M1 - 6502
ER -